Gilead Sciences (Gilead Sciences) COGS-to-Revenue

: 0.29 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

Gilead Sciences's Cost of Goods Sold for the three months ended in Dec. 2023 was $2,090 Mil. Its Revenue for the three months ended in Dec. 2023 was $7,114 Mil.

Gilead Sciences's COGS to Revenue for the three months ended in Dec. 2023 was 0.29.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Gilead Sciences's Gross Margin % for the three months ended in Dec. 2023 was 70.62%.

Gilead Sciences COGS-to-Revenue Historical Data

The historical data trend for Gilead Sciences's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

0.21

0.19

0.24

0.21

0.24

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue																0.19	0.22	0.22	0.22	0.29

Gilead Sciences COGS-to-Revenue Calculation

Gilead Sciences's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	6498	/	27116
	=	0.24

Gilead Sciences's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	2090	/	7114
	=	0.29

Gilead Sciences (NAS:GILD) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Gilead Sciences's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	2090 / 7114
	=	70.62 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Gilead Sciences COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (Gilead Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Executives

Andrew D Dickinson	officer: EVP, Chief Financial Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Johanna Mercier	officer: Chief Commercial Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey	officer: Chief Medical Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson	officer: SVP, Controllership	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong	officer: SVP, Controller & CAO	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman	officer: EVP, Corporate Affairs & GC	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher	officer: EVP, Gen Counsel & Corp Sec	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Jeffrey Bluestone	director	C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Anthony Welters	director
Javier Rodriguez	director	601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan	director	2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson	director	C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold	director	C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711